Securities Litigation Alert: Pacira Pharmaceuticals Investors Encouraged to Contact Faruqi & Faruqi, LLP
Investors who have suffered losses in Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) are encouraged to contact Faruqi & Faruqi, LLP’s securities litigation partner, James (Josh) Wilson, directly to discuss their potential legal options. The law firm is investigating potential securities laws violations at the company.
Background on Pacira Pharmaceuticals
Pacira Pharmaceuticals is a specialty pharmaceutical company that focuses on the clinical and commercial development, manufacturing, and sale of innovative and essential pain and wound care therapies. The company’s flagship product is EXPAREL, an injectable local anesthetic used to provide long-term postsurgical pain relief. The drug has been approved by the FDA for use in various surgical procedures, including orthopedic, urologic, and gynecologic surgeries.
Investigation into Pacira Pharmaceuticals
Faruqi & Faruqi, LLP’s investigation into Pacira Pharmaceuticals follows a report by short-seller, Citron Research, which alleged that EXPAREL’s sales growth was due to an illegal kickback scheme. The report claimed that Pacira paid kickbacks to pain clinics and anesthesia groups in exchange for prescribing EXPAREL to patients, inflating sales figures and artificially boosting the company’s stock price.
Impact on Investors
If the allegations are proven to be true, Pacira Pharmaceuticals investors may be able to recover their losses through a securities class action lawsuit. The investigation is ongoing, and more information will be provided as it becomes available. Investors who purchased Pacira Pharmaceuticals securities between January 1, 2018, and October 23, 2019, are encouraged to contact Faruqi & Faruqi, LLP to discuss their potential claims.
Impact on the Industry
The allegations against Pacira Pharmaceuticals could have far-reaching implications for the pharmaceutical industry as a whole. If the kickback scheme is proven to be widespread, it could lead to increased scrutiny and regulation of the industry. This could result in increased costs for pharmaceutical companies, as they are required to comply with new regulations, and decreased profits for those found to be engaging in illegal activities.
Contact Information
If you invested in Pacira Pharmaceuticals and wish to discuss your potential legal options, please contact Faruqi & Faruqi, LLP’s securities litigation partner, James (Josh) Wilson, at 877-247-4292 or [email protected]. The law firm has significant experience in prosecuting securities fraud class actions and has recovered billions of dollars for investors.
Conclusion
The investigation into Pacira Pharmaceuticals by Faruqi & Faruqi, LLP follows allegations of an illegal kickback scheme that inflated sales figures and artificially boosted the company’s stock price. If the allegations are proven to be true, Pacira Pharmaceuticals investors may be able to recover their losses through a securities class action lawsuit. The investigation could also have far-reaching implications for the pharmaceutical industry as a whole, leading to increased scrutiny and regulation. If you invested in Pacira Pharmaceuticals and wish to discuss your potential legal options, please contact Faruqi & Faruqi, LLP’s securities litigation partner, James (Josh) Wilson, at 877-247-4292 or [email protected].
- Pacira Pharmaceuticals is under investigation for potential securities laws violations
- Investors who suffered losses are encouraged to contact Faruqi & Faruqi, LLP
- Allegations of illegal kickback scheme inflating sales figures and stock price
- Impact on investors: potential recovery through securities class action lawsuit
- Impact on industry: increased scrutiny and regulation
- Contact information: Faruqi & Faruqi, LLP’s securities litigation partner, James (Josh) Wilson
